
Sanofi (AKA: Aventis Pharmaceuticals) Profile last edited on: 7/3/2019
NO Business Identifier is currently available for this company. Year Founded
1970Last Involved Year
2021Key People / Management
Christopher A Viehbacher -- CEO
Anjan Aralihalli --
Ira C Baeringer --
Mark Black --
Sylvaine Cases -- External Innovation in the West Coast Office
Hsien C Cheng --
David R Compton --
Hugues Corbeil --
Marc G Corrado -- Director
John E Cullity --
George De Sanctis -- Director, Scouting & Partnering US, Prospective & Strategic Initiatives
Alejandro Donoso -- Director, Technology Lice
Gerd Fischer --
David Ghesquiere -- Director, Global Business
Sanjay Gupta --
Daniel J Izzo --
E Todd Johnson --
Eric T Johnson -- Director, Financial Evalu
Shabnam Kazmi --
Sathapana Kongsamut --
Shiv Krishnan -- Senior Director, Scouting & Partnering
John Landy --
Lewis K Lee -- Director, Portfolio & Pro
Xiang Liao -- Sr. Manager Business Deve
David Malek --
Christine C Mayer -- Vice President
Sridaran Natesan --
Kevin P O'Brien --
Daniel R Pascheles -- VP Corporate Development
Bernd W Petermann -- Director, Global Business
Margaret Petty --
Thomas J Rice -- Director, U.S. New Produc
Charles R Struby -- VP, New Products Commerci
David Thorpe --
Darcy B Toms -- Director, Global Business
Benoit Vanasse --
Tanja S Weber -- Director, Business Develo
Thomas Wiatrowski --
Carole A Wilmot -- Senior Director; US Busin
Hugh Wilson -- Director-Corporate Develo
Michael A Yeomans -- Vice President, Head of G
John S Zawad -- VP, Aventis Capital
Anjan Aralihalli --
Ira C Baeringer --
Mark Black --
Sylvaine Cases -- External Innovation in the West Coast Office
Hsien C Cheng --
David R Compton --
Hugues Corbeil --
Marc G Corrado -- Director
John E Cullity --
George De Sanctis -- Director, Scouting & Partnering US, Prospective & Strategic Initiatives
Alejandro Donoso -- Director, Technology Lice
Gerd Fischer --
David Ghesquiere -- Director, Global Business
Sanjay Gupta --
Daniel J Izzo --
E Todd Johnson --
Eric T Johnson -- Director, Financial Evalu
Shabnam Kazmi --
Sathapana Kongsamut --
Shiv Krishnan -- Senior Director, Scouting & Partnering
John Landy --
Lewis K Lee -- Director, Portfolio & Pro
Xiang Liao -- Sr. Manager Business Deve
David Malek --
Christine C Mayer -- Vice President
Sridaran Natesan --
Kevin P O'Brien --
Daniel R Pascheles -- VP Corporate Development
Bernd W Petermann -- Director, Global Business
Margaret Petty --
Thomas J Rice -- Director, U.S. New Produc
Charles R Struby -- VP, New Products Commerci
David Thorpe --
Darcy B Toms -- Director, Global Business
Benoit Vanasse --
Tanja S Weber -- Director, Business Develo
Thomas Wiatrowski --
Carole A Wilmot -- Senior Director; US Busin
Hugh Wilson -- Director-Corporate Develo
Michael A Yeomans -- Vice President, Head of G
John S Zawad -- VP, Aventis Capital
Location Information
174 Avenue De France Cedex 13
Paris, FR 75635
Paris, FR 75635
(331) 537-74000 |
en.sanofi-aventis.com |
Public Profile
Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France. Formerly known as Sanofi-Aventis, Sanofi SA is a pharmaceutical company, contributes to enhancing life by providing an offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company has products in the areas of thrombosis, cardiovascular, metabolic diseases, oncology, central nervous system, internal medicine, and vaccines. Its primary medicines include Lovenox/Clexane, Plavix/Iscover, Aprovel/Avapro/Karvea, Tritace/Triatec/Delix/Altace, Lantus, Amaryl/Amarel/Solosa, Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. The company?s vaccines principally include pediatric combination and poliomyelitis vaccines, influenza vaccines, meningitis/pneumonia vaccines, adult and adolescent booster vaccines, and travel and endemic vaccines. It has collaboration agreements principally with Novozymes, Dyax Corp., Oxford BioMedica, Regeneron, IDM, Zealand Pharma, UCB, and Crucell N.V., as well as partners, including Immunogen, Coley, Wayne State University, Innogenetics, Inserm, and Micromet Inc. The company also has an agreement with Drugs For Neglected Diseases Initiative (dndi) for the development, manufacturing, and distribution of fexinidazole, a drug for the treatment of human African trypanosomiasis; and a licensing agreement with Wellstat Therapeutics Corporation to develop, manufacture, and commercialize PN2034, an oral insulin sensitizer for the treatment of Type II diabetes. In addition, the company has interest in Merial Limited, an animal health company that provides a range of products to enhance the health, well-being, and performance of animals. It has a strategic antibody collaboration agreement with Regeneron Pharmaceuticals Inc. to discover, develop, and commercialize human therapeutic monoclonal antibodies. Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France.